FORM 6 - K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of November 1999
Commission File Number 0-29350
VASOGEN INC.
(Translation of Registrant's name into English)
2155 Dunwin Drive, Suite 10, Mississauga, Ontario, L5L 4M1
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20 - F or Form 40 - F.)
Form 20 - F [ X ] Form 40 - F [ ]
(Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes [ ] No [ X ]
This Form 6-K consists of:
Form 8-A for registration of certain classes of securities pursuant to section
12 (b) or (g) of the securities exchange act of 1934.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VASOGEN INC.
By /s/Christopher Waddick
-------------------------------------
(Name: Christopher Waddick)
(Title: Vice-President, Finance & CFO)
Date: November 22, 1999
<PAGE>
Vasogen Inc. INVESTOR CONTACT
2155 Dunwin Drive, Suite 10 Trevor Burns
Mississauga, ON, Canada L5L 4M1 Investor Relations
tel (905) 569-2265 fax (905) 569-9231 tel (905) 569-9065
http://www.vasogen.com e-mail [email protected]
- --------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
VASOGEN TO LIST ON THE AMERICAN STOCK EXCHANGE
Toronto, Ontario (November 22, 1999) - Vasogen Inc. (TSE:VAS; OTC BB:VSOGF) is
pleased to announce that the Company's common shares have been approved for
listing on The American Stock Exchange. Vasogen has chosen Spear Leeds &
Kellogg, of New York, New York, to serve as specialist or "market-maker" on the
floor of the Exchange. The Registrar and Transfer Company of Cranford, New
Jersey, has been retained to act as co-transfer agent in the United States.
Trading on the AMEX under the symbol "MEW" will commence on November 23, 1999.
Upon commencement of AMEX trading, the OTC BB listing will be discontinued.
Vasogen is focused on developing immune modulation therapies to advance the
treatment of cardiovascular, autoimmune and related inflammatory diseases.
These therapies are designed to target fundamental disease-causing
events, providing safe, effective treatment.
Statements contained in this press release, including those pertaining to
scientific and clinical research, commercialization plans, strategic alliances,
and intellectual property protection, other than statements of historical fact,
are forward-looking statements subject to a number of uncertainties that could
cause actual results to differ materially from statements made.
